LEADER
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 9,340 patients with type 2 diabetes at high cardiovascular risk, liraglutide reduced major adverse cardiovascular events compared with placebo.
N
9340
Disegno
Double-blind RCT
Esito
CV death, MI or stroke
Rilevanza
2
Risultato13.0 % vs 14.9 % (HR 0.87); CV and all-cause mortality reduced.
Marso SP, et al. N Engl J Med. 2016;375(4):311-322. 10.1056/NEJMoa1603827
Discussione e critica
Established the cardiovascular benefit of GLP-1 receptor agonists — roughly a 14 % MACE reduction is now regarded as a class effect.